Bristol Myers Squibb's CAMZYOS offers benefits in oHCM trial
Bristol Myers Squibb presents long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-LTE trial, showing sustained efficacy and safety of CAMZYOS in treating NYHA class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM) over 3.5 years, with consistent improvements in echocardiographic measures and biomarkers, and most patients reaching NYHA class I.
Reference News
Bristol Myers Squibb presents long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-LTE trial, showing sustained efficacy and safety of CAMZYOS in treating NYHA class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM) over 3.5 years, with consistent improvements in echocardiographic measures and biomarkers, and most patients reaching NYHA class I.